SPONSORS
OctOBER 28 - DAY 1
|
8:15-9:00 |
Continental Breakfast |
||||
|
8:45-9:00 |
Welcome & Announcements
Ron Dolle, PhD, Director of the Center for Drug Discovery WashU Center for Drug Discovery |
||||
|
9:00 – 10:00 |
Opening Keynote
Reimagining Drugability using Chemoproteomic Platforms Daniel Nomura, PhD University of California, Berkeley Frontier Medicine |
||||
| 10:00 - 10:30 | Coffee Break | ||||
|
10:30 - 12:00 |
Session 1: New Approach Methods (NAMs) in DDD |
||||
|
10:30 |
Pluripotent stem cell directed model of autosomal dominant polycystic kidney disease for mechanism and drug discovery Jack Song, PhD University of Alabama, Birmingham |
||||
| 11:00 |
|
||||
|
11:30 |
|
||||
|
12:00 - 1:15 |
LUNCH (included) |
||||
|
1:15 - 2:45 |
Session 2: Advancing Your Innovation |
||||
| 1:15 |
Gary Robinson, PhD NIH/NCI |
||||
|
1:45 |
 Drug Discovery and Development at WashU: The Needleman Program
Shripad Bhagwat, PhD Needleman Program for Innovation and Commercialization at WashU Medicine |
||||
| 2:15 |
D. Brian Shortel, PhD Ballard Spahr LLP |
||||
|
2:55 - 3:15 |
Coffee Break |
||||
|
3:15 - 4:15 |
Session 3: Lessons in Perseverance |
||||
|
3:15 |
The Development of mGlu4 Positive Allosteric Modulators for the Treatment of Parkinson’s Disease Colleen Niswender, PhD Vanderbilt University |
||||
| 3:45 |
Guillermo Vela, MS, BA CEO, NeuScience |
||||
|
4:15 - 4:45 |
Session 4: Posters Lightning Round Selected trainees will have 5 minutes to present their posters on stage |
||||
| 4:45 - 5:15 | Poster Mounting | ||||
|
5:15 - 7:15 |
Welcome Reception with Posters (poster judging) |
Oct. 29 - DAY 2
|
8:15 - 9:00 |
Continental Breakfast |
|
| 8:45 - 9:00 |
Welcome & Announcements
Ron Dolle, PhD Director of the Center for Drug Discovery, Washington University of St. Louis |
|
|
9:00 – 10:30 |
Session 5: Funding Sources for 2026 and Beyond |
|
|
9:00 |
The Translational Therapeutics Accelerator (TRxA): Maturing Your Academic Asset In University Walls Maaike Everts, PhD Critical Path Institute |
|
| 9:20 |
Due Diligence? What Does “Good” Look Like & How Might We Prepare? Michael Myers, PhD Associate Vice President & Head of Due Diligence, Eli Lilly & Co. |
|
| 9:40 |
Biotech Venture Capital in 2026: What do VCs look for? Ryan Sullivan, PhD Curie.Bio |
|
| 10:00 | Panel Discussion | |
| 10:30 - 11:00 |
Coffee Break |
|
|
11:00 – 11:30 |
Session 6: IMPACT Lightning Round Three 10-minute program overviews, selected from IMPACT database submissions |
|
| 11:00 |
Speaker 1 |
|
| 11:10 |
Speaker 2 |
|
| 11:20 |
Speaker 3 |
|
| 11:30 - 12:00 | Session 7: Awards & Recognitions | |
|
Paige Vinson, PhD ADDC / Southern Research |
||
| 12:00 - 1:15 |
LUNCH (included) |
|
|
1:15 - 2:15 |
Session 8: Novel Approaches to Discovery |
|
|
1:15 |
Casey Krusemark, PhD Purdue University |
|
| 1:45 |
.png)
Computationally driven drug discovery as a platform for a new generation DDC Vsevolod Katritch, PhD Professor of Quantitative & Computational Biology, Chemistry and Pharmacology, University of Southern California |
|
| 2:15 - 2:45 | Coffee Break | |
|
2:45 – 3:45 |
Closing Keynote: Learning From the Past, Looking to the Future |
|
|
Title TBD Matthew D. Hall, PhD NIH/NCATS |
||
|
3:45 – 4:00 |
Closing Remarks / Adjourn
Ron Dolle, PhD Director of the Center for Drug Discovery, Washington University of St. Louis |
|
| 4:30 - 6:30 | Biogenerator Startup Incubator Reception (Advance RSVP required; limited space) | at The Cortex |
|
|
Jim McCarter Sr. Managing Director, Biogenerator Ventures Sr. Vice President BioSTL |
|
|
Crystal Winkeler Managing Director, Biogenerator Ventures |
KEYNOTE SPEAKERs |
|
|
